Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Forecasted to Post Q1 2025 Earnings of ($1.16) Per Share

Inovio Pharmaceuticals, Inc. (NASDAQ:INO - Free Report) - Investment analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Inovio Pharmaceuticals in a report issued on Tuesday, May 14th. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will post earnings per share of ($1.16) for the quarter. The consensus estimate for Inovio Pharmaceuticals' current full-year earnings is ($4.09) per share. HC Wainwright also issued estimates for Inovio Pharmaceuticals' Q2 2025 earnings at ($1.07) EPS, Q3 2025 earnings at ($0.99) EPS and Q4 2025 earnings at $1.20 EPS.

Several other analysts have also commented on the company. Stephens started coverage on Inovio Pharmaceuticals in a report on Tuesday. They set an "overweight" rating and a $20.00 price objective for the company. StockNews.com downgraded shares of Inovio Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Friday, April 5th. Royal Bank of Canada reiterated a "sector perform" rating on shares of Inovio Pharmaceuticals in a research note on Thursday, March 7th. Finally, Oppenheimer upgraded shares of Inovio Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $48.00 price target on the stock in a research note on Thursday, January 25th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $70.67.

Inovio Pharmaceuticals Trading Up 14.4 %

NASDAQ:INO traded up $1.65 during midday trading on Wednesday, reaching $13.07. 729,771 shares of the stock traded hands, compared to its average volume of 483,290. Inovio Pharmaceuticals has a 12-month low of $3.89 and a 12-month high of $14.75. The business has a 50-day moving average of $11.30 and a two-hundred day moving average of $36.97.

Inovio Pharmaceuticals (NASDAQ:INO - Get Free Report) last released its quarterly earnings results on Monday, May 13th. The biopharmaceutical company reported ($1.31) EPS for the quarter, missing the consensus estimate of ($1.08) by ($0.23). Inovio Pharmaceuticals had a negative net margin of 16,238.91% and a negative return on equity of 80.79%. During the same quarter in the previous year, the business earned ($1.92) EPS.

Institutional Trading of Inovio Pharmaceuticals

Several large investors have recently made changes to their positions in the business. Vanguard Personalized Indexing Management LLC purchased a new stake in Inovio Pharmaceuticals in the third quarter valued at $42,000. Pathstone Family Office LLC boosted its stake in shares of Inovio Pharmaceuticals by 344.2% in the third quarter. Pathstone Family Office LLC now owns 148,392 shares of the biopharmaceutical company's stock worth $58,000 after buying an additional 114,989 shares during the last quarter. Prime Capital Investment Advisors LLC boosted its stake in shares of Inovio Pharmaceuticals by 213.5% in the third quarter. Prime Capital Investment Advisors LLC now owns 138,972 shares of the biopharmaceutical company's stock worth $54,000 after buying an additional 94,637 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in Inovio Pharmaceuticals during the third quarter worth about $178,000. Finally, Keystone Financial Group raised its position in Inovio Pharmaceuticals by 11.7% during the fourth quarter. Keystone Financial Group now owns 122,737 shares of the biopharmaceutical company's stock valued at $63,000 after acquiring an additional 12,840 shares in the last quarter. 26.79% of the stock is owned by hedge funds and other institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.